Abbott scrutinizes Sandoz’ Biaxin generics
Executive Summary
Abbott says it will evaluate Sandoz' clarithromycin ANDAs and take "appropriate measures to protect its intellectual property" covering the Biaxin franchise. FDA approved Sandoz' ANDAs for clarithromycin immediate- and extended-release on Aug. 25; the products have not yet launched. Abbott is in patent litigation with several companies to keep Biaxin XL generics off the market, but Sandoz is not part of that litigation. Immediate-release Biaxin generics launched in May upon expiration of Abbott's compound patent...